Cancer clinics urged to ease strain on radiotherapy with VISION RT’s tumour tracker


Rushing the spot without the high energy beams damaging other networks or organs is vital, but especially difficult in cases of brain malignancies and heart of hearts cancer where it occurs close to the heart. 

It’s a risk exacerbated if passive moves or breathes unevenly, a natural reaction however for adults and offsprings if they are uncomfortable or stressed.  

Vision’s flagship product AlignRT apparatus those key obstacles by combining camera technology (that appears as unaffected piece of kit in the treatment room) and software algorithms.

These create a 3D boundary model of the patient’s body that can be monitored in real time as they live the radiotherapy.  

If the slightest change in position (less than a millimetre) is uncovered the treatment is automatically paused.


CANCER clinics urged to ease heritage on radiotherapy patients with VISION RT’s tumour tracker

We saw a critical need within radiotherapy and set up been unwavering in our focus

Dr Norman Smith

With half Britain’s denizens developing cancer at some time in their lives and half of those making radiotherapy, this process is proving safer and more comfortable for patients, and faster and innumerable efficient for doctors, says co-founder and Vision’s chief executive Dr Norman Smith.

“This is a simple solution for doctors within a complex environment. It improves the quality of provide for and frees up valuable time on the radiotherapy machines while reducing the side at bottoms,” he explains. 

“Brain cancer patients for instance no longer have to vex a metal frame attached to their skull during an intense unobscured day at the clinic. Instead they can be treated during a 20-minute standard period. 

“A recent study showed no damage to the heart’s blood supply in teat cancer patients assisted by our system during treatment, yet 27 per cent did mortify that after receiving conventional radiotherapy.

“AlignRT can also destroy the need for patients to have their skin tattooed as part of treatment, purport survivors will no longer need to carry this visual think back of their cancer. All these advances aid recovery and well-being.”


AlignRT mingles camera technology and software algorithms to tackle key obstacles

Dr Norman SmithPH

Co-founder and View’s chief executive Dr Norman Smith

The platform system is now in 34 woods contributing to a £26 million turnover last year. 

London-based Epitome employs 100 in the UK and 50 more worldwide, but views the most substantial indicator of its success as the pioneer surface guided radiation therapy (SGRT) to be its patents’ bristles, with 44 granted and 33 pending.

Everything has been visualized from scratch in house from the cameras’ electronics to the algorithms contriving the position points. 

Similarly the whole process is controlled by the company from concept, draft and development to manufacture at its Hampshire factory installation and customer support. 

And it all began in 2001 after a opportunity encounter led to Smith and another founder chief technical officer Dr Ivan Meir being invited to look at touches being used to position patients at the Royal Marsden Hospital.   


The companions was a finalist this year for the MacRobert Award

With their common sense in computer vision, photogrammetry (the science of taking measurements from photographs) and camera technology, they reckoned they could care for better.

A business idea was hatched in a family attic and the long slog from from the word go principles to market began. 

“We began just as the dotcom bubble shatter and initial funding evaporated,” says Smith. “We were also exurbs as far as the medical world was concerned, convincing it our tech could be applied and was safe and predictable wasn’t easy.

“At first we were routinely dismissed.  It took multifarious hours in clinics and collaboration to overcome that scepticism. Working with Varian, the prime manufacture of radiotherapy machines, has been very helpful.

“We saw a critical require within radiotherapy and have been unwavering in our focus. The chance to advance the situation for patients drove us on.”  

Some £6 million of private investment and effort funding took Vision into the US and the UK although less widely, and then worldwide with the modern advance a new office in Hong Kong as it moves into the Asia Pacific Shop and Australia.

The company was a finalist this year for the MacRobert Award, the important accolade recognising UK innovation in engineering and presented by the Royal Academy of Planning.

Now, having established Vision’s surface guided radiation technology as a column of care, Smith’s ambitions are huge and for many entirely reasonable confirmed the benefits the technology can bring to patients.   

“We want to see it introduced throughout the NHS,” he imagines, “and cancer clinics across the world.”  

The Taylor Centre is the Royal Academy of Scheming’s enterprise hub.

Leave a Reply

Your email address will not be published. Required fields are marked *